Evidence map›Paper›PMID 30973190›Full record

ArticlePediatric transplantation2019

Extracorporeal membrane oxygenation use in the first 24 hours following pediatric heart transplantation: Incidence, risk factors, and outcomes.

Justin Godown, David W Bearl, Cary Thurm, Matt Hall, Brian Feingold, Jonathan H Soslow, Bret A Mettler, Andrew H Smith, Elizabeth L Profita, Tajinder P Singh and 1 more

Abstract read
In one paragraph

Article in Pediatric transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Justin GodownPediatric Cardiology, Monroe Carell Jr. Children's Hospital, Nashville, Tennessee.ORCID 0000-0002-7068-0625
David W BearlPediatric Cardiology, Monroe Carell Jr. Children's Hospital, Nashville, Tennessee.
Cary ThurmChildren's Hospital Association, Lenexa, Kansas.
Matt HallChildren's Hospital Association, Lenexa, Kansas.
Brian FeingoldPediatrics and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0003-4244-709X
Jonathan H SoslowPediatric Cardiology, Monroe Carell Jr. Children's Hospital, Nashville, Tennessee.
Bret A MettlerPediatric Cardiothoracic Surgery, Monroe Carell Jr. Children's Hospital, Nashville, Tennessee.
Andrew H SmithPediatric Critical Care, Monroe Carell Jr. Children's Hospital, Nashville, Tennessee.
Elizabeth L ProfitaPediatric Cardiology, Lucile Packard Children's Hospital at Stanford, Palo Alto, California.
Tajinder P SinghPediatric Cardiology, Boston Children's Hospital, Boston, Massachusetts.
Debra A DoddPediatric Cardiology, Monroe Carell Jr. Children's Hospital, Nashville, Tennessee.

Funding

Quantitative Assessment of Cardiac Disease in Duchenne Muscular DystrophyK23HL123938 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SOSLOW, JONATHAN HARVEY · 2014 to 2018
$829k
NHLBI NIH HHS K23 HL123938NHLBI NIH HHS K23HL123938
6 · The paper itself

Abstract

Primary graft dysfunction following HTx is associated with significant morbidity and mortality. This study aimed to assess the incidence of, risk factors for, and outcomes of children requiring ECMO within 24 hours of HTx. This study utilized a linked PHIS/SRTR database of pediatric HTx recipients (2002-2016). Post-HTx ECMO was identified using inpatient billing data. Logistic regression assessed risk factors for post-HTx ECMO. Kaplan-Meier analyses assessed in-hospital mortality and post-discharge survival. A total of 2820 patients were included with 224 (7.9%) requiring ECMO. Independent risk factors for post-HTx ECMO include age <1 year (aOR: 2.2, 95% CI: 1.3-3.7, P = 0.006) or 1-5 years (aOR: 2.1, 95% CI: 1.3-3.4, P = 0.002), and ECMO support at HTx (aOR: 27.4, 95% CI: 15.2-49.6, P < 0.001). Survival to discharge decreased with increasing duration of post-HTx ECMO support; 89% for 1-3 days, 79.1% for 4-6 days, 63.2% for 7-9 days, and 18.8% for ≥10 days. There was no difference in long-term survival for patients requiring post-HTx ECMO who survived to hospital discharge (P = 0.434). There are identifiable risk factors associated with the need for ECMO in the post-HTx period. Length of time on ECMO post-HTx is strongly associated with the risk of in-hospital mortality. Patients who require ECMO early post-HTx and survive to discharge have comparable outcomes to patients who did not require ECMO.

Indexed as

Extracorporeal Membrane OxygenationAdolescentChildChild, PreschoolFemaleGraft RejectionGraft SurvivalHeart-Assist DevicesHeart FailureHeart TransplantationHumansIncidenceInfantKaplan-Meier EstimateMalePrimary Graft Dysfunctionextracorporeal membrane oxygenationgraft failuregraft functionpediatric heart transplant

Identifiers

PMID30973190
PMCPMC6548572

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.